Document:

Exhibit 4.1

    
      

    

    

      EXHIBIT
        4.1

      

      THIS
        NOTE AND THE COMMON SHARES ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT
        BEEN
        REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THIS NOTE AND THE
        COMMON SHARES ISSUABLE UPON CONVERSION OF THIS NOTE MAY NOT BE SOLD, OFFERED
        FOR
        SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION
        STATEMENT AS TO THIS NOTE UNDER SAID ACT OR AN OPINION OF COUNSEL REASONABLY
        SATISFACTORY TO THE MEDICAL EXCHANGE INC. THAT SUCH REGISTRATION IS NOT
        REQUIRED.

      

      Principal
        Amount $___________                                                Issue
        Date: ____, 2007

      Purchase
        Price $_____________

      

      SECURED
        CONVERTIBLE NOTE

      

      FOR
        VALUE
        RECEIVED, THE MEDICAL EXCHANGE INC., a Nevada corporation (hereinafter called
        "Borrower"), hereby promises to pay to _____________ (the "Holder") or order,
        without demand, the sum of ______________ ($__________), with interest accruing
        thereon, on _________, 2007 (120 days after issuance) (the "Maturity Date"),
        if
        not retired sooner.

      

      This
        Note
        has been entered into pursuant to the terms of a subscription agreement between
        the Borrower and the Holder, dated of even date herewith (the “Subscription
        Agreement”), and shall be governed by the terms of such Subscription Agreement.
        Unless otherwise separately defined herein, all capitalized terms used in
        this
        Note shall have the same meaning as is set forth in the Subscription Agreement.
        The following terms shall apply to this Note:

      

      ARTICLE
        I

      

      GENERAL
        PROVISIONS

      

      1.1 Default
        Interest Rate.
        Following the occurrence and during the continuance of an Event of Default,
        which, if susceptible to cure is not cured within ten (10) days, otherwise
        then
        from the first date of such occurrence, the annual interest rate on this
        Note
        shall (subject to Section 4.7) be fifteen percent (15%) and calculated on
        a 365
        day year.

      

      1.2 Payment
        Grace Period.
        The
        Borrower shall have a five (5) day grace period to pay any monetary amounts
        due
        under this Note, after which grace period a default interest rate of fifteen
        percent (15%) per annum.

      

      1.3 Conversion
        Privileges.
        The
        Conversion Privileges set forth in Article II shall remain in full force
        and
        effect immediately from the date hereof and until the Note is paid in full
        regardless of the occurrence of an Event of Default. The Note shall be payable
        in full on the Maturity Date, unless previously converted into Common Stock
        in
        accordance with Article II hereof; provided, that if an Event of Default
        has
        occurred, the Borrower may not pay this Note, without the consent of the
        Holder,
        until one year after the later of the date the Event of Default has been
        cured
        or one year after the Maturity Date.

      

        
          
            
            

          

          
            
            

            
              

            

          

          
            
            

          

        

      

       

      1.4 Restricted
        Shares.
        In the
        event this Note is not repaid on the Maturity Date, the Company shall issue
        daily to the Holder, 500 Shares of restricted stock of the Company for each
        $100,000 of Purchase Price until such time as the Note is repaid. Such Shares
        of
        stock shall have the same registration rights described in Section 11 of
        the
        Subscription Agreement.

      

      ARTICLE
        II

      

      CONVERSION
        RIGHTS

      

      The
        Holder shall have the right to convert the principal and any interest due
        under
        this Note into Shares of the Borrower's Common Stock, $.001 par value per
        share
        (“Common Stock”) as set forth below.

      

      2.1. Conversion
        into the Borrower's Common Stock.

      

      (a) The
        Holder shall have the right from and after the date of the issuance of this
        Note
        and then at any time until this Note is fully paid, to convert any outstanding
        and unpaid principal portion of this Note, and accrued interest, at the election
        of the Holder (the date of giving of such notice of conversion being a
        "Conversion Date") into fully paid and nonassessable shares of Common Stock
        as
        such stock exists on the date of issuance of this Note, or any shares of
        capital
        stock of Borrower into which such Common Stock shall hereafter be changed
        or
        reclassified, at the conversion price as defined in Section 2.1(b) hereof
        (the
        "Conversion Price"), determined as provided herein. Upon delivery to the
        Borrower of a completed Notice of Conversion, a form of which is annexed
        hereto,
        Borrower shall issue and deliver to the Holder within three (3) business
        days
        after the Conversion Date (such third day being the “Delivery Date”) that number
        of shares of Common Stock for the portion of the Note converted in accordance
        with the foregoing. At the election of the Holder, the Borrower will deliver
        accrued but unpaid interest on the Note, if any, through the Conversion Date
        directly to the Holder on or before the Delivery Date (as defined in the
        Subscription Agreement). The number of shares of Common Stock to be issued
        upon
        each conversion of this Note shall be determined by dividing that portion
        of the
        principal of the Note and interest, if any, to be converted, by the Conversion
        Price.

      

      (b)  Subject
        to adjustment as provided in Section 2.1(c) hereof, the Conversion Price
        per
        share shall be $5.00. Beginning one year after the Closing Date, the Conversion
        Price shall be the lesser of (i) $5.00 (“Fixed Conversion Price”), or (ii)
        seventy-five percent (75%) of the average of the closing bid prices of the
        Common Stock as reported by Bloomberg L.P. for the Principal Market for the
        five
        trading days preceding but not including the Conversion Date.

      

      (c) 
        The
        Fixed Conversion Price and number and kind of shares or other securities
        to be
        issued upon conversion determined pursuant to Section 2.1(a), shall be subject
        to adjustment from time to time upon the happening of certain events while
        this
        conversion right remains outstanding, as follows:

      

      A. Merger,
        Sale of Assets, etc. If the Borrower at any time shall consolidate with or
        merge
        into or sell or convey all or substantially all its assets to any other
        corporation, this Note, as to the unpaid principal portion thereof and accrued
        interest thereon, shall thereafter be deemed to evidence the right to purchase
        such number and kind of shares or other securities and property as would
        have
        been issuable or distributable on account of such consolidation, merger,
        sale or
        conveyance, upon or with respect to the securities subject to the conversion
        or
        purchase right immediately prior to such consolidation, merger, sale or
        conveyance. The foregoing provision shall similarly apply to successive
        transactions of a similar nature by any such successor or purchaser. Without
        limiting the generality of the foregoing, the anti-dilution provisions of
        this
        Section shall apply to such securities of such successor or purchaser after
        any
        such consolidation, merger, sale or conveyance.

      

        
          
            
            

          

          
            
            

            
              

            

          

          
            
            

          

        

      B. Reclassification,
        etc. If the Borrower at any time shall, by reclassification or otherwise,
        change
        the Common Stock into the same or a different number of securities of any
        class
        or classes that may be issued or outstanding, this Note, as to the unpaid
        principal portion thereof and accrued interest thereon, shall thereafter
        be
        deemed to evidence the right to purchase an adjusted number of such securities
        and kind of securities as would have been issuable as the result of such
        change
        with respect to the Common Stock immediately prior to such reclassification
        or
        other change.

      

      C. Stock
        Splits, Combinations and Dividends. If the shares of Common Stock are subdivided
        or combined into a greater or smaller number of shares of Common Stock, or
        if a
        dividend is paid on the Common Stock in shares of Common Stock, the Conversion
        Price shall be proportionately reduced in case of subdivision of shares or
        stock
        dividend or proportionately increased in the case of combination of shares,
        in
        each such case by the ratio which the total number of shares of Common Stock
        outstanding immediately after such event bears to the total number of shares
        of
        Common Stock outstanding immediately prior to such event..

       

      D. Share
        Issuance. So long as this Note is outstanding, if the Borrower shall issue
        or
        agree to issue any shares of Common Stock except for the Excepted Issuances
        (as
        defined in the Subscription Agreement) for a consideration less than the
        Conversion Price in effect at the time of such issue, then, and thereafter
        successively upon each such issue, the Conversion Price shall be reduced
        to such
        other lower issue price. For purposes of this adjustment, the issuance of
        any
        security carrying the right to convert such security into shares of Common
        Stock
        or of any warrant, right or option to purchase Common Stock shall result
        in an
        adjustment to the Conversion Price upon the issuance of the above-described
        security and again upon the issuance of shares of Common Stock upon exercise
        of
        such conversion or purchase rights if such issuance is at a price lower than
        the
        then applicable Conversion Price. The reduction of the Conversion Price
        described in this paragraph is in addition to other rights of the Holder
        described in this Note and the Subscription Agreement.

      

      (d) Whenever
        the Conversion Price is adjusted pursuant to Section 2.1(c) above, the Borrower
        shall promptly mail to the Holder a notice setting forth the Conversion Price
        after such adjustment and setting forth a statement of the facts requiring
        such
        adjustment.

      

      (e) During
        the period the conversion right exists, Borrower will reserve from its
        authorized and unissued Common Stock not less than an amount of Common Stock
        equal to 200% of the amount of shares of Common Stock issuable upon the full
        conversion of this Note. Borrower represents that upon issuance, such shares
        will be duly and validly issued, fully paid and non-assessable. Borrower
        agrees
        that its issuance of this Note shall constitute full authority to its officers,
        agents, and transfer agents who are charged with the duty of executing and
        issuing stock certificates to execute and issue the necessary certificates
        for
        shares of Common Stock upon the conversion of this Note.

      

      2.2 Method
        of Conversion.
        This
        Note may be converted by the Holder in whole or in part as described in Section
        2.1(a) hereof and the Subscription Agreement. Upon partial conversion of
        this
        Note, a new Note containing the same date and provisions of this Note shall,
        at
        the request of the Holder, be issued by the Borrower to the Holder for the
        principal balance of this Note and interest which shall not have been converted
        or paid.

      

      2.3 Maximum
        Conversion.
        The
        Holder shall not be entitled to convert on a Conversion Date that amount
        of the
        Note in connection with that number of shares of Common Stock which would
        be in
        excess of the sum of (i) the number of shares of Common Stock beneficially
        owned
        by the Holder and its affiliates on a Conversion Date, (ii) any Common Stock
        issuable in connection with the unconverted portion of the Note, and (iii)
        the
        number of shares of Common Stock issuable upon the conversion of the Note
        with
        respect to which the determination of this provision is being made on a
        Conversion Date, which would result in beneficial ownership by the Holder
        and
        its affiliates of more than 4.99% of the outstanding shares of Common Stock
        of
        the Borrower on such Conversion Date. For the purposes of the provision to
        the
        immediately preceding sentence, beneficial ownership shall be determined
        in
        accordance with Section 13(d) of the Securities Exchange Act of 1934, as
        amended, and Regulation 13d-3 thereunder. Subject to the foregoing, the Holder
        shall be limited to aggregate conversions of 4.99%. The Holder shall have
        the
        authority and obligation to determine whether the restriction contained in
        this
        Section 2.3 will limit any conversion hereunder and to the extent that the
        Holder determines that the limitation contained in this Section applies,
        the
        determination of which portion of the Notes are convertible shall be the
        responsibility and obligation of the Holder. The Holder may waive the conversion
        limitation described in this Section 2.3, in whole or in part, upon and
        effective after 61 days prior written notice to the Borrower to increase
        such
        percentage to up to 9.99%.

      

        
          
            
            

          

          
            
            

            
              

            

          

          
            
            

          

        

      ARTICLE
        III

      

      EVENT
        OF DEFAULT

      

      The
        occurrence of any of the following events of default ("Event of Default")
        shall,
        at the option of the Holder hereof, make all sums of principal and interest
        then
        remaining unpaid hereon and all other amounts payable hereunder immediately
        due
        and payable, upon demand, without presentment, or grace period, all of which
        hereby are expressly waived, except as set forth below:

      

      3.1 Failure
        to Pay Principal or Interest.
        The
        Borrower fails to pay any installment of principal, interest or other sum
        due
        under this Note when due and such failure continues for a period of five
        (5)
        days after the due date. The five (5) day period described in this Section
        3.1
        is the same five (5) day period described in Section 1.2 hereof.

      

      3.2 Breach
        of Covenant.
        The
        Borrower breaches any material covenant or other term or condition of the
        Subscription Agreement or this Note in any material respect and such breach,
        if
        subject to cure, continues for a period of ten (10) business days after written
        notice to the Borrower from the Holder.

      

      3.3 Breach
        of Representations and Warranties.
        Any
        material representation or warranty of the Borrower made herein, in the
        Subscription Agreement, or in any agreement, statement or certificate given
        in
        writing pursuant hereto or in connection therewith shall be false or misleading
        in any material respect as of the date made and the Closing Date.

      

      3.4 Receiver
        or Trustee.
        The
        Borrower shall make an assignment for the benefit of creditors, or apply
        for or
        consent to the appointment of a receiver or trustee for it or for a substantial
        part of its property or business; or such a receiver or trustee shall otherwise
        be appointed.

      

      3.5 Judgments.
        Any
        money judgment, writ or similar final process shall be entered or filed against
        Borrower or any of its property or other assets for more than $150,000, and
        shall remain unvacated, unbonded or unstayed for a period of forty-five (45)
        days. 

      

      3.6 Bankruptcy.
        Bankruptcy, insolvency, reorganization or liquidation proceedings or other
        proceedings or relief under any bankruptcy law or any law, or the issuance
        of
        any notice in relation to such event, for the relief of debtors shall be
        instituted by or against the Borrower and if instituted against Borrower
        are not
        dismissed within 45 days of initiation.

      

      3.7 Delisting.
        Delisting of the Common Stock from any Principal Market; failure to comply
        with
        the requirements for continued listing on a Principal Market for a period
        of
        seven consecutive trading days; or notification from a Principal Market that
        the
        Borrower is not in compliance with the conditions for such continued listing
        on
        such Principal Market.

      

      3.8 Non-Payment.
        A
        default by the Borrower under any one or more obligations in an aggregate
        monetary amount in excess of $100,000 for more than twenty days after the
        due
        date, unless the Borrower is contesting the validity of such obligation in
        good
        faith.

      

        
          
            
            

          

          
            
            

            
              

            

          

          
            
            

          

        

      3.9 Stop
        Trade.
        An SEC
        or judicial stop trade order or Principal Market trading suspension that
        lasts
        for five or more consecutive trading days.

      

      3.10 Failure
        to Deliver Common Stock or Replacement Note.
        Borrower's failure to timely deliver Common Stock to the Holder pursuant
        to and
        in the form required by this Note and Sections 7 and 11 of the Subscription
        Agreement, or, if required, a replacement Note.

      

      3.11 Non-Registration
        Event.
        The
        occurrence of a Non-Registration Event as described in Section 11.4 of the
        Subscription Agreement.

      

      3.12 Reservation
        Default.
        Failure
        by the Borrower to have reserved for issuance upon conversion of the Note
        the
        amount of Common stock as set forth in this Note and the Subscription
        Agreement.

      

      3.13 Cross
        Default.
        A
        default by the Borrower of a material term, covenant, warranty or undertaking
        of
        any other agreement to which the Borrower and Holder are parties, or the
        occurrence of a material event of default under any such other agreement
        which
        is not cured after any required notice and/or cure period.

      

      ARTICLE
        IV

      

      SECURITY
        INTEREST

       

                      4. Security
        Interest/Waiver of Automatic Stay.
        This
        Note is secured by a security interest granted to the Collateral Agent for
        the
        benefit of the Holder pursuant to a Security Agreement, as delivered by Borrower
        to Holder. The Borrower acknowledges and agrees that should a proceeding
        under
        any bankruptcy or insolvency law be commenced by or against the Borrower,
        or if
        any of the Collateral (as defined in the Security Agreement) should become
        the
        subject of any bankruptcy or insolvency proceeding, then the Holder should
        be
        entitled to, among other relief to which the Holder may be entitled under
        the
        Transaction Documents and any other agreement to which the Borrower and Holder
        are parties (collectively, "Loan Documents") and/or applicable law, an order
        from the court granting immediate relief from the automatic stay pursuant
        to 11
        U.S.C. Section 362 to permit the Holder to exercise all of its rights and
        remedies pursuant to the Loan Documents and/or applicable law. THE BORROWER
        EXPRESSLY WAIVES THE BENEFIT OF THE AUTOMATIC STAY IMPOSED BY 11 U.S.C. SECTION
        362. FURTHERMORE, THE BORROWER EXPRESSLY ACKNOWLEDGES AND AGREES THAT NEITHER
        11
        U.S.C. SECTION 362 NOR ANY OTHER SECTION OF THE BANKRUPTCY CODE OR OTHER
        STATUTE
        OR RULE (INCLUDING, WITHOUT LIMITATION, 11 U.S.C. SECTION 105) SHALL STAY,
        INTERDICT, CONDITION, REDUCE OR INHIBIT IN ANY WAY THE ABILITY OF THE HOLDER
        TO
        ENFORCE ANY OF ITS RIGHTS AND REMEDIES UNDER THE LOAN DOCUMENTS AND/OR
        APPLICABLE LAW. The Borrower hereby consents to any motion for relief from
        stay
        that may be filed by the Holder in any bankruptcy or insolvency proceeding
        initiated by or against the Borrower and, further, agrees not to file any
        opposition to any motion for relief from stay filed by the Holder. The Borrower
        represents, acknowledges and agrees that this provision is a specific and
        material aspect of the Loan Documents, and that the Holder would not agree
        to
        the terms of the Loan Documents if this waiver were not a part of this Note.
        The
        Borrower further represents, acknowledges and agrees that this waiver is
        knowingly, intelligently and voluntarily made, that neither the Holder nor
        any
        person acting on behalf of the Holder has made any representations to induce
        this waiver, that the Borrower has been represented (or has had the opportunity
        to he represented) in the signing of this Note and the Loan Documents and
        in the
        making of this waiver by independent legal counsel selected by the Borrower
        and
        that the Borrower has discussed this waiver with counsel.

      

        
          
            
            

          

          
            
            

            
              

            

          

          
            
            

          

        

      ARTICLE
        V

      

      MISCELLANEOUS

      

      5.1 Failure
        or Indulgence Not Waiver.
        No
        failure or delay on the part of Holder hereof in the exercise of any power,
        right or privilege hereunder shall operate as a waiver thereof, nor shall
        any
        single or partial exercise of any such power, right or privilege preclude
        other
        or further exercise thereof or of any other right, power or privilege. All
        rights and remedies existing hereunder are cumulative to, and not exclusive
        of,
        any rights or remedies otherwise available.

      

      5.2 Notices.
        All
        notices, demands, requests, consents, approvals, and other communications
        required or permitted hereunder shall be in writing and, unless otherwise
        specified herein, shall be (i) personally served, (ii) deposited in the mail,
        registered or certified, return receipt requested, postage prepaid, (iii)
        delivered by reputable air courier service with charges prepaid, or (iv)
        transmitted by hand delivery, telegram, or facsimile, addressed as set forth
        below or to such other address as such party shall have specified most recently
        by written notice. Any notice or other communication required or permitted
        to be
        given hereunder shall be deemed effective (a) upon hand delivery or delivery
        by
        facsimile, with accurate confirmation generated by the transmitting facsimile
        machine, at the address or number designated below (if delivered on a business
        day during normal business hours where such notice is to be received), or
        the
        first business day following such delivery (if delivered other than on a
        business day during normal business hours where such notice is to be received)
        or (b) on the second business day following the date of mailing by express
        courier service, fully prepaid, addressed to such address, or upon actual
        receipt of such mailing, whichever shall first occur. The addresses for such
        communications shall be: (i) if to the Borrower to: The
        Medical Exchange Inc., 17 State Street, New York, NY 10004, with
        a
        copy by telecopier only to: Aboudi & Brounstein, 3 Gavish St., Kfar Saba,
        Israel, Fax: 972-9-764-4834, and (ii) if to the Holder, to the name, address
        and
        telecopy number set forth on the front page of this Note, with a copy by
        telecopier only to Grushko & Mittman, P.C., 551 Fifth Avenue, Suite 1601,
        New York, New York 10176, telecopier number: (212) 697-3575.

      

      5.3 Amendment
        Provision.
        The
        term "Note" and all reference thereto, as used throughout this instrument,
        shall
        mean this instrument as originally executed, or if later amended or
        supplemented, then as so amended or supplemented.

      

      5.4 Assignability.
        This
        Note shall be binding upon the Borrower and its successors and assigns, and
        shall inure to the benefit of the Holder and its successors and
        assigns.

      

      5.5 Cost
        of Collection.
        If
        default is made in the payment of this Note, Borrower shall pay the Holder
        hereof reasonable costs of collection, including reasonable attorneys'
        fees.

      

      5.6 Governing
        Law.
        This
        Note shall be governed by and construed in accordance with the laws of the
        State
        of New York. Any action brought by either party against the other concerning
        the
        transactions contemplated by this Agreement shall be brought only in the
        state
        courts of New York or in the federal courts located in the state of New York.
        Both parties and the individual signing this Agreement on behalf of the Borrower
        agree to submit to the jurisdiction of such courts. The prevailing party
        shall
        be entitled to recover from the other party its reasonable attorney's fees
        and
        costs.

      

      5.7 Maximum
        Payments.
        Nothing
        contained herein shall be deemed to establish or require the payment of a
        rate
        of interest or other charges in excess of the maximum permitted by applicable
        law. In the event that the rate of interest required to be paid or other
        charges
        hereunder exceed the maximum permitted by such law, any payments in excess
        of
        such maximum shall be credited against amounts owed by the Borrower to the
        Holder and thus refunded to the Borrower.

      

      5.8 Shareholder
        Status.
        The
        Holder shall not have rights as a shareholder of the Borrower with respect
        to
        unconverted portions of this Note. However, the Holder will have all the
        rights
        of a shareholder of the Borrower with respect to the shares of Common Stock
        to
        be received by Holder after delivery by the Holder of a Conversion Notice
        to the
        Borrower.

      

        
          
            
            

          

          
            
            

            
              

            

          

          
            
            

          

        

      

       

      [THIS
        SPACE INTENTIONALLY LEFT BLANK]

      

      
        
          
          

        

        
          
          

          
            

          

        

        
          
          

        

      

      IN
        WITNESS WHEREOF,
        Borrower has caused this Note to be signed in its name by an authorized officer
        as of the ____ day of ________, 2007.

      

                                  THE
        MEDICAL EXCHANGE
INC.

      

      

      

                                  By:________________________________

                                  Name:

                                  Title:

       

      WITNESS:

      

      

      ______________________________________

      
        
          
          

        

        
          
          

          
            

          

        

        
          
          

        

      

      NOTICE
        OF CONVERSION

      

      (To
        be
        executed by the Registered Holder in order to convert the Note)

      

      

      The
        undersigned hereby elects to convert $_________ of the principal and $_________
        of the interest due on the Note issued by The Medical Exchange Inc. on March
        ____, 2007 into Shares of Common Stock of The Medical Exchange Inc. (the
        "Borrower") according to the conditions set forth in such Note, as of the
        date
        written below.

      

      

      

      Date
        of
        Conversion:___________________________________________________________________________________________________________________________

      

      

      Conversion
        Price:_____________________________________________________________________________________________________________________________

      

      

      Shares
        To
        Be
        Delivered:________________________________________________________________________________________________________________________

       

       

      Signature:___________________________________________________________________________________________________________________________________

      

      

      Print
        Name:__________________________________________________________________________________________________________________________________

      

      

      Address:____________________________________________________________________________________________________________________________________

      

      ____________________________________________________________________________________________________________________________________Exhibit 4.2

    
      

    

    EXHIBIT
      4.2

    

    THIS
      WARRANT AND THE COMMON SHARES ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE NOT
      BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THIS WARRANT
      AND
      THE COMMON SHARES ISSUABLE UPON EXERCISE OF THIS WARRANT MAY NOT BE SOLD,
      OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE
      REGISTRATION STATEMENT UNDER SAID ACT OR AN OPINION OF COUNSEL REASONABLY
      SATISFACTORY TO THE MEDICAL EXCHANGE INC. THAT SUCH REGISTRATION IS NOT
      REQUIRED.

    

    
      	 	
              Right
                to Purchase ___________shares of Common Stock of The Medical Exchange
                Inc.
                (subject to adjustment as provided
                herein)

            

    

    

    CLASS
      A COMMON STOCK PURCHASE WARRANT

    No. 2007-A-___                                                                    Issue
      Date: ____, 2007

     

    The
      Medical Exchange Inc., a corporation organized under the laws of the State
      of
      Nevada (the “Company”), hereby certifies that, for value received,
      _______________, or its assigns
      (the “Holder”), is entitled, subject to the terms set forth below, to purchase
      from the Company at any time after the Issue Date until 5:00 p.m., E.S.T on
      the
      fifth anniversary of the Actual Effective Date (as defined in Section 11.1(iv)
      of the Subscription Agreement) (the “Expiration Date”), ___________fully paid
      and nonassessable shares of Common Stock at a per share purchase price of $5.00.
      The aforedescribed purchase price per share, as adjusted from time to time
      as
      herein provided, is referred to herein as the “Purchase Price.” The number and
      character of such shares of Common Stock and the Purchase Price are subject
      to
      adjustment as provided herein. The Company may reduce the Purchase Price without
      the consent of the Holder. Capitalized terms used and not otherwise defined
      herein shall have the meanings set forth in that certain Subscription Agreement
      (the “Subscription
      Agreement”),
      dated
      February 28, 2007, entered into by the Company and Holders.

     

    As
      used
      herein the following terms, unless the context otherwise requires, have the
      following respective meanings: 

     

    (a) The
      term
“Company” shall mean The
      Medical Exchange Inc.
      and any
      corporation which shall succeed or assume the obligations of The
      Medical Exchange Inc.
      hereunder. 

     

    (b) The
      term
“Common Stock” includes (a) the Company’s common stock, $0.001 par value
      per share, as authorized on the date of the Subscription Agreement, and (b)
      any
      Other Securities into which or for which any of the securities described in
      (a) may be converted or exchanged pursuant to a plan of recapitalization,
      reorganization, merger, sale of assets or otherwise.

     

    (c) The
      term
“Other Securities” refers to any stock (other than Common Stock) and other
      securities of the Company or any other person (corporate or otherwise) which
      the
      holder of the Warrant at any time shall be entitled to receive, or shall have
      received, on the exercise of the Warrant, in lieu of or in addition to Common
      Stock, or which at any time shall be issuable or shall have been issued in
      exchange for or in replacement of Common Stock or Other Securities pursuant
      to
      Section 5 or otherwise. 

     

    (d) The
      term
“Warrant Shares” shall mean the Common Stock issuable upon exercise of this
      Warrant.

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    1. Exercise
      of Warrant.

     

    1.1. Number
      of Shares Issuable upon Exercise.
      From
      and after the Issue Date through and including the Expiration Date, the Holder
      hereof shall be entitled to receive, upon exercise of this Warrant in whole
      in
      accordance with the terms of subsection 1.2 or upon exercise of this
      Warrant in part in accordance with subsection 1.3, Common Stock of the
      Company, subject to adjustment pursuant to Section 4.

     

    1.2. Full
      Exercise.
      This
      Warrant may be exercised in full by the Holder hereof by delivery of an original
      or facsimile copy of the form of subscription attached as Exhibit A hereto
      (the “Subscription Form”) duly executed by such Holder and surrender of the
      original Warrant within four (4) days of exercise, to the Company at its
      principal office or at the office of its Warrant Agent (as provided
      hereinafter), accompanied by payment, in cash, wire transfer or by certified
      or
      official bank check payable to the order of the Company, in the amount obtained
      by multiplying the number of shares of Common Stock for which this Warrant
      is
      then exercisable by the Purchase Price then in effect. 

     

    1.3. Partial
      Exercise.
      This
      Warrant may be exercised in part (but not for a fractional share) by surrender
      of this Warrant in the manner and at the place provided in subsection 1.2
      except that the amount payable by the Holder on such partial exercise shall
      be
      the amount obtained by multiplying (a) the number of whole shares of Common
      Stock designated by the Holder in the Subscription Form by (b) the Purchase
      Price then in effect. On any such partial exercise, the Company, at its expense,
      will forthwith issue and deliver to or upon the order of the Holder hereof
      a new
      Warrant of like tenor, in the name of the Holder hereof or as such Holder (upon
      payment by such Holder of any applicable transfer taxes) may request, the whole
      number of shares of Common Stock for which such Warrant may still be exercised
      for the balance of.

     

    1.4. Fair
      Market Value.
      Fair
      Market Value of a share of Common Stock as of a particular date (the
“Determination Date”) shall mean: 

     

    (a) If
      the
      Company’s Common Stock is traded on an exchange or is quoted on the National
      Association of Securities Dealers, Inc. Automated Quotation (“NASDAQ”), National
      Market System, the NASDAQ Capital Market or the American Stock Exchange, LLC,
      then the closing or last sale price, respectively, reported for the last
      business day immediately preceding the Determination Date;

     

    (b) If
      the
      Company’s Common Stock is not traded on an exchange or on the NASDAQ National
      Market System, the NASDAQ Capital Market or the American Stock Exchange, Inc.,
      but is traded in the over-the-counter market, then the average of the closing
      bid and ask prices reported for the last business day immediately preceding
      the
      Determination Date;

     

    (c) Except
      as
      provided in clause (d) below, if the Company’s Common Stock is not publicly
      traded, then as the Holder and the Company agree, or in the absence of such
      an
      agreement, by arbitration in accordance with the rules then standing of the
      American Arbitration Association, before a single arbitrator to be chosen from
      a
      panel of persons qualified by education and training to pass on the matter
      to be
      decided; or

     

    (d) If
      the
      Determination Date is the date of a liquidation, dissolution or winding up,
      or
      any event deemed to be a liquidation, dissolution or winding up pursuant to
      the
      Company’s charter, then all amounts to be payable per share to holders of the
      Common Stock pursuant to the charter in the event of such liquidation,
      dissolution or winding up, plus all other amounts to be payable per share in
      respect of the Common Stock in liquidation under the charter, assuming for
      the
      purposes of this clause (d) that all of the shares of Common Stock then
      issuable upon exercise of all of the Warrants are outstanding at the
      Determination Date.

    
       

      
        
          
          

        

        
          
          

          
            

          

        

        
          
          

        

         

      

    

    1.5. Company
      Acknowledgment.
      The
      Company will, at the time of the exercise of the Warrant, upon the request
      of
      the Holder hereof acknowledge in writing its continuing obligation to afford
      to
      such Holder any rights to which such Holder shall continue to be entitled after
      such exercise in accordance with the provisions of this Warrant. If the Holder
      shall fail to make any such request, such failure shall not affect the
      continuing obligation of the Company to afford to such Holder any such
      rights.

     

    1.6. Trustee
      for Warrant Holders.
      In the
      event that a qualified bank or trust company shall have been appointed as
      trustee for the Holder of the Warrants pursuant to Subsection 3.2, such
      bank or trust company shall have all the powers and duties of a warrant agent
      (as hereinafter described) and shall accept, in its own name for the account
      of
      the Company or such successor person as may be entitled thereto, all amounts
      otherwise payable to the Company or such successor, as the case may be, on
      exercise of this Warrant pursuant to this Section 1. 

     

    1.7. Delivery
      of Stock Certificates, etc. on Exercise.
      The
      Company agrees that the shares of Common Stock purchased upon exercise of this
      Warrant shall be deemed to be issued to the Holder hereof as the record owner
      of
      such shares as of the close of business on the date on which this Warrant shall
      have been surrendered and payment made for such shares as aforesaid. As soon
      as
      practicable after the exercise of this Warrant in full or in part, and in any
      event within four (4) business
      days
      thereafter (“Warrant Share Delivery Date”), the Company at its expense
      (including the payment by it of any applicable issue taxes) will cause to be
      issued in the name of and delivered to the Holder hereof, or as such Holder
      (upon payment by such Holder of any applicable transfer taxes) may direct in
      compliance with applicable securities laws, a certificate or certificates for
      the number of duly and validly issued, fully paid and nonassessable shares
      of
      Common Stock (or Other Securities) to which such Holder shall be entitled on
      such exercise, plus, in lieu of any fractional share to which such Holder would
      otherwise be entitled, cash equal to such fraction multiplied by the then Fair
      Market Value of one full share of Common Stock, together with any other stock
      or
      other securities and property (including cash, where applicable) to which such
      Holder is entitled upon such exercise pursuant to Section 1 or otherwise.
      The Company understands that a delay in the delivery of the Warrant Shares
      after
      the Warrant Share Delivery Date could result in economic loss to the Holder.
      As
      compensation to the Holder for such loss, the Company agrees to pay (as
      liquidated damages and not as a penalty) to the Holder for late issuance of
      Warrant Shares upon exercise of this Warrant the amount of $100 per business
      day
      after the Warrant Share Delivery Date for each $10,000 of Purchase Price of
      Warrant Shares for which this Warrant is exercised which are not timely
      delivered. The Company shall pay any payments incurred under this Section in
      immediately available funds upon demand. Furthermore, in addition to any other
      remedies which may be available to the Holder, in the event that the Company
      fails for any reason to effect delivery of the Warrant Shares by the Warrant
      Share Delivery Date, the Holder may revoke all or part of the relevant Warrant
      exercise by delivery of a notice to such effect to the Company whereupon the
      Company and the Holder shall each be restored to their respective positions
      immediately prior to the exercise of the relevant portion of this Warrant,
      except that the liquidated damages described above shall be payable through
      the
      date notice of revocation or rescission is given to the Company. 

     

    2. Cashless
      Exercise.

     

    (a) Payment
      upon exercise may be made at the option of the Holder either in (i) cash,
      wire transfer or by certified or official bank check payable to the order of
      the
      Company equal to the applicable aggregate Purchase Price, (ii) by cashless
      exercise in accordance with Section (b) below or (iii) by a
      combination of any of the foregoing methods, for the number of shares of Common
      Stock specified in such form (as such exercise number shall be adjusted to
      reflect any adjustment in the total number of shares of Common Stock issuable
      to
      the Holder per the terms of this Warrant) and the Holder shall thereupon be
      entitled to receive the number of duly authorized, validly issued, fully-paid
      and non-assessable shares of Common Stock (or Other Securities) determined
      as
      provided herein.

    
       

      
        
          
          

        

        
          
          

          
            

          

        

        
          
          

        

         

      

    

    (b) If
      the
      Fair Market Value of one share of Common Stock is greater than the Purchase
      Price (at the date of calculation as set forth below), in lieu of exercising
      this Warrant for cash, the Holder may elect to receive shares equal to the
      value
      (as determined below) of this Warrant (or the portion thereof being cancelled)
      by surrender of this Warrant at the principal office of the Company together
      with the properly endorsed Subscription Form in which event the Company shall
      issue to the Holder a number of shares of Common Stock computed using the
      following formula:

     

    X=Y
      (A-B)

                                                              
      A

     

    
      
        
          	                               
                  Where	
                  X=

                	
                  the
                    number of shares of Common Stock to be issued to the
                    holder

                

        

         

      

    

    
      	 	
              Y=

            	
              the
                number of shares of Common Stock purchasable under the Warrant or,
                if only
                a portion of the Warrant is being exercised, the portion of the Warrant
                being exercised (at the date of such
                calculation)

            

    

     

    
      	 	
              A=

            	
              the
                average of the three highest closing sale prices of the Common Stock
                for
                the five (5) Trading Days immediately prior to (but not including)
                the
                Exercise Date

            

    

     

    
      	 	
              B=

            	
              Purchase
                Price (as adjusted to the date of such
                calculation)

            

    

     

    For
      purposes of Rule 144 promulgated under the 1933 Act, it is intended, understood
      and acknowledged that the Warrant Shares issued in a cashless exercise
      transaction shall be deemed to have been acquired by the Holder, and the holding
      period for the Warrant Shares shall be deemed to have commenced, on the date
      this Warrant was originally issued pursuant to the Subscription
      Agreement.

     

    3. Adjustment
      for Reorganization, Consolidation, Merger, etc.

     

    3.1. Reorganization,
      Consolidation, Merger, etc.
      In case
      at any time or from time to time, the Company shall (a) effect a
      reorganization, (b) consolidate with or merge into any other person or
      (c) transfer all or substantially all of its properties or assets to any
      other person under any plan or arrangement contemplating the dissolution of
      the
      Company, then, in each such case, as a condition to the consummation of such
      a
      transaction, proper and adequate provision shall be made by the Company whereby
      the Holder of this Warrant, on the exercise hereof as provided in
      Section 1, at any time after the consummation of such reorganization,
      consolidation or merger or the effective date of such dissolution, as the case
      may be, shall receive, in lieu of the Common Stock (or Other Securities)
      issuable on such exercise prior to such consummation or such effective date,
      the
      stock and other securities and property (including cash) to which such Holder
      would have been entitled upon such consummation or in connection with such
      dissolution, as the case may be, if such Holder had so exercised this Warrant,
      immediately prior thereto, all subject to further adjustment thereafter as
      provided in Section 4.

     

    3.2. Dissolution.
      In the
      event of any dissolution of the Company following the transfer of all or
      substantially all of its properties or assets, the Company, prior to such
      dissolution, shall at its expense deliver or cause to be delivered the stock
      and
      other securities and property (including cash, where applicable) receivable
      in
      accordance with Section 3.1 by the Holder upon their exercise after the
      effective date of such dissolution pursuant to this Section 3 to a bank or
      trust company (a “Trustee”) having its principal office in New York, NY, as
      trustee for the Holder. 

     

    3.3. Continuation
      of Terms.
      Upon
      any reorganization, consolidation, merger or transfer (and any dissolution
      following any transfer) referred to in this Section 3, this Warrant shall
      continue in full force and effect and the terms hereof shall be applicable
      to
      the Other Securities and property receivable on the exercise of this Warrant
      after the consummation of such reorganization, consolidation or merger or the
      effective date of dissolution following any such transfer, as the case may
      be,
      and shall be binding upon the issuer of any Other Securities, including, in
      the
      case of any such transfer, the person acquiring all or substantially all of
      the
      properties or assets of the Company, whether or not such person shall have
      expressly assumed the terms of this Warrant as provided in Section 4. In
      the event this Warrant does not continue in full force and effect after the
      consummation of the transaction described in this Section 3, then only in
      such event will the Company’s securities and property (including cash, where
      applicable) receivable by the Holder of the Warrants be delivered to the Trustee
      as contemplated by Section 3.2.

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

       

    

    3.4 Share
      Issuance.
      Until
      the Expiration Date, if the Company shall issue any Common Stock except for
      the
      Excepted Issuances (as defined in the Subscription Agreement), prior to the
      complete exercise of this Warrant for a consideration less than the Purchase
      Price that would be in effect at the time of such issue, then, and thereafter
      successively upon each such issue, the Purchase Price shall be reduced to such
      other lower purchase price. For purposes of this adjustment, the issuance of
      any
      security or debt instrument of the Company carrying the right to convert such
      security or debt instrument into Common Stock or of any warrant, right or option
      to purchase Common Stock shall result in an adjustment to the Purchase Price
      upon the issuance of the above-described security, debt instrument, warrant,
      right, or option if such issuance is at a price lower than the Purchase Price
      in
      effect upon such issuance. The reduction of the Purchase Price described in
      this
      Section 3.4 is subject to the provisions of, and in addition to the other rights
      of the Holder described in, the Subscription Agreement.

     

    4. Extraordinary
      Events Regarding Common Stock.
      In the
      event that the Company shall (a) issue additional shares of the Common
      Stock as a dividend or other distribution on outstanding Common Stock,
      (b) subdivide its outstanding shares of Common Stock, or (c) combine
      its outstanding shares of the Common Stock into a smaller number of shares
      of
      the Common Stock, then, in each such event, the Purchase Price shall,
      simultaneously with the happening of such event, be adjusted by multiplying
      the
      then Purchase Price by a fraction, the numerator of which shall be the number
      of
      shares of Common Stock outstanding immediately prior to such event and the
      denominator of which shall be the number of shares of Common Stock outstanding
      immediately after such event, and the product so obtained shall thereafter
      be
      the Purchase Price then in effect. The Purchase Price, as so adjusted, shall
      be
      readjusted in the same manner upon the happening of any successive event or
      events described herein in this Section 4. The number of shares of Common
      Stock that the Holder of this Warrant shall thereafter, on the exercise hereof
      as provided in Section 1, be entitled to receive shall be adjusted to a
      number determined by multiplying the number of shares of Common Stock that
      would
      otherwise (but for the provisions of this Section 4) be issuable on such
      exercise by a fraction of which (a) the numerator is the Purchase Price
      that would otherwise (but for the provisions of this Section 4) be in
      effect, and (b) the denominator is the Purchase Price in effect on the date
      of such exercise.

     

    5. Certificate
      as to Adjustments.
      In each
      case of any adjustment or readjustment in the shares of Common Stock issuable
      on
      the exercise of the Warrants, the Company at its expense will promptly cause
      its
      Chief Financial Officer or other appropriate designee to compute such adjustment
      or readjustment in accordance with the terms of the Warrant and prepare a
      certificate setting forth such adjustment or readjustment and showing in detail
      the facts upon which such adjustment or readjustment is based, including a
      statement of (a) the consideration received or receivable by the Company
      for any additional shares of Common Stock issued or sold or deemed to have
      been
      issued or sold, (b) the number of shares of Common Stock outstanding or
      deemed to be outstanding, and (c) the Purchase Price and the number of
      shares of Common Stock to be received upon exercise of this Warrant, in effect
      immediately prior to such adjustment or readjustment and as adjusted or
      readjusted as provided in this Warrant. The Company will forthwith mail a copy
      of each such certificate to the Holder of the Warrant and any Warrant Agent
      of
      the Company (appointed pursuant to Section 11 hereof).

     

    6. Reservation
      of Stock, etc. Issuable on Exercise of Warrant; Financial
      Statements.
      The
      Company will at all times reserve and keep available, solely for issuance and
      delivery on the exercise of the Warrants, all shares of Common Stock from time
      to time issuable on the exercise of the Warrant. This Warrant entitles the
      Holder hereof to receive copies of all financial and other information
      distributed or required to be distributed to the holders of the Company’s Common
      Stock. 

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

       

    

    7. Assignment;
      Exchange of Warrant.
      Subject
      to compliance with applicable securities laws, this Warrant, and the rights
      evidenced hereby, may be transferred by any registered holder hereof (a
“Transferor”). On the surrender for exchange of this Warrant, with the
      Transferor’s endorsement in the form of Exhibit B attached hereto (the
“Transferor Endorsement Form”) and together with an opinion of counsel
      reasonably satisfactory to the Company that the transfer of this Warrant will
      be
      in compliance with applicable securities laws, the Company at its expense,
      twice, only, but with payment by the Transferor of any applicable transfer
      taxes, will issue and deliver to or on the order of the Transferor thereof
      a new
      Warrant or Warrants of like tenor, in the name of the Transferor and/or the
      transferee(s) specified in such Transferor Endorsement Form (each a
“Transferee”), calling in the aggregate on the face or faces thereof for the
      number of shares of Common Stock called for on the face or faces of the Warrant
      so surrendered by the Transferor. No such transfers shall result in a public
      distribution of the Warrant.

     

    8. Replacement
      of Warrant.
      On
      receipt of evidence reasonably satisfactory to the Company of the loss, theft,
      destruction or mutilation of this Warrant and, in the case of any such loss,
      theft or destruction of this Warrant, on delivery of an indemnity agreement
      or
      security reasonably satisfactory in form and amount to the Company or, in the
      case of any such mutilation, on surrender and cancellation of this Warrant,
      the
      Company at its expense, twice only, will execute and deliver, in lieu thereof,
      a
      new Warrant of like tenor.

     

    9. Registration
      Rights.
      The
      Holder of this Warrant has been granted certain registration rights by the
      Company. These registration rights are set forth in the Subscription Agreement.
      The terms of the Subscription Agreement are incorporated herein by this
      reference.

     

    10. Maximum
      Exercise.
      The
      Holder shall not be entitled to exercise this Warrant on an exercise
      date, in
      connection with that number of shares of Common Stock which would be in excess
      of the sum of (i) the number of shares of Common Stock beneficially owned
      by the Holder and its affiliates on an exercise date, and (ii) the number
      of shares of Common Stock issuable upon the exercise of this Warrant with
      respect to which the determination of this limitation is being made on an
      exercise date, which would result in beneficial ownership by the Holder and
      its
      affiliates of not more than 4.99% of the outstanding shares of Common Stock
      on
      such date. For the purposes of the immediately preceding sentence, beneficial
      ownership shall be determined in accordance with Section 13(d) of the
      Securities Exchange Act of 1934, as amended, and Regulation 13d-3 thereunder.
      Subject to the foregoing, the Holder shall be limited to aggregate exercises
      which would result in the issuance of more than 4.99%. The
      restriction described in this paragraph may be waived, in whole or in part,
      upon sixty-one (61) days prior notice from the Holder to the Company to increase
      such percentage to up to 9.99%, but not in excess of 9.99%. The Holder may
      decide whether to convert a Convertible Note or exercise this Warrant to achieve
      an actual 4.99% or up to 9.99% ownership position as described above, but not
      in
      excess of 9.99%.

     

    11. Warrant
      Agent.
      The
      Company may, by written notice to the Holder of the Warrant, appoint an agent
      (a
“Warrant Agent”) for the purpose of issuing Common Stock on the exercise of this
      Warrant pursuant to Section 1, exchanging this Warrant pursuant to
      Section 7, and replacing this Warrant pursuant to Section 8, or any of
      the foregoing, and thereafter any such issuance, exchange or replacement, as
      the
      case may be, shall be made at such office by such Warrant Agent. 

     

    12. Transfer
      on the Company’s Books.
      Until
      this Warrant is transferred on the books of the Company, the Company may treat
      the registered holder hereof as the absolute owner hereof for all purposes,
      notwithstanding any notice to the contrary. 

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

       

    

    13. Notices.
      All
      notices, demands, requests, consents, approvals, and other communications
      required or permitted hereunder shall be in writing and, unless otherwise
      specified herein, shall be (i) personally served, (ii) deposited in the mail,
      registered or certified, return receipt requested, postage prepaid, (iii)
      delivered by reputable air courier service with charges prepaid, or (iv)
      transmitted by hand delivery, telegram, or facsimile, addressed as set forth
      below or to such other address as such party shall have specified most recently
      by written notice. Any notice or other communication required or permitted
      to be
      given hereunder shall be deemed effective (a) upon hand delivery or delivery
      by
      facsimile, with accurate confirmation generated by the transmitting facsimile
      machine, at the address or number designated below (if delivered on a business
      day during normal business hours where such notice is to be received), or the
      first business day following such delivery (if delivered other than on a
      business day during normal business hours where such notice is to be received)
      or (b) on the second business day following the date of mailing by express
      courier service, fully prepaid, addressed to such address, or upon actual
      receipt of such mailing, whichever shall first occur or
      (c)
      three business days after deposited in the mail if delivered pursuant to
      subsection (ii) above.
      The
      addresses for such communications shall be: (i) if to the Company to:
The
      Medical Exchange Inc., 17 State Street, New York, NY 10004, with
      a
      copy by telecopier only to: Aboudi & Brounstein, 3 Gavish St., Kfar Saba,
      Israel, Fax: 972-9-764-4834, and (ii) if to the Holder, to the addresses and
      telecopier number set forth in the first paragraph of this Warrant, with an
      additional copy by telecopier only to: Grushko & Mittman, P.C., 551 Fifth
      Avenue, Suite 1601, New York, New York 10176, telecopier number: (212)
      697-3575.

     

    14. Miscellaneous.
      This
      Warrant and any term hereof may be changed, waived, discharged or terminated
      only by an instrument in writing signed by the party against which enforcement
      of such change, waiver, discharge or termination is sought. This Warrant shall
      be construed and enforced in accordance with and governed by the laws of New
      York. Any dispute relating to this Warrant shall be adjudicated in New York
      County in the State of New York. The headings in this Warrant are for purposes
      of reference only, and shall not limit or otherwise affect any of the terms
      hereof. The invalidity or unenforceability of any provision hereof shall in
      no
      way affect the validity or enforceability of any other provision. 

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    IN
      WITNESS WHEREOF, the Company has executed this Warrant as of the date first
      written above. 

     

                                            THE
      MEDICAL EXCHANGE
      INC.

    
       

       

       

                                              By:    
        _________________________________        

                                           Name:

                                           Title:

    

     

     

    Witness:

     

     

    ___________________________________________________

    

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    Exhibit A

    FORM
      OF
      SUBSCRIPTION

    (to
      be
      signed only on exercise of Warrant)

    TO:
      The
      Medical Exchange Inc.

     

    The
      undersigned, pursuant to the provisions set forth in the attached Warrant
      (No.____), hereby irrevocably elects to purchase (check applicable
      box):

    

    ___ ________
      shares of the Common Stock covered by such Warrant; or

     

    ___ the
      maximum number of shares of Common Stock covered by such Warrant pursuant to
      the
      cashless exercise procedure set forth in Section 2.

    

    The
      undersigned herewith makes payment of the full purchase price for such shares
      at
      the price per share provided for in such Warrant, which is $___________. Such
      payment takes the form of (check applicable box or boxes):

    ___ $__________
      in lawful money of the United States; and/or

     

    ___ the
      cancellation of the Warrant to the extent necessary, in accordance with the
      formula set forth in Section 2, to exercise this Warrant with respect to
      the maximum number of shares of Common Stock purchasable pursuant to the
      cashless exercise procedure set forth in Section 2.

    

    The
      undersigned requests that the certificates for such shares be issued in the
      name
      of, and delivered to _____________________________________________________
      whose
      address is
      __________________________________________________________________________________________________________________________________________________________________________

    Number
      of
      Shares of Common Stock Beneficially Owned on the date of exercise: Less
      than
      five percent (5%) of the outstanding Common Stock of The Medical Exchange
      Inc.

    The
      undersigned represents and warrants that the representations and warranties
      in
      Section 4 of the Subscription Agreement (as defined in this Warrant) are true
      and accurate with respect to the undersigned on the date hereof.

    

    The
      undersigned represents and warrants that all offers and sales by the undersigned
      of the securities issuable upon exercise of the within Warrant shall be made
      pursuant to registration of the Common Stock under the Securities Act of 1933,
      as amended (the “Securities Act”), or pursuant to an exemption from registration
      under the Securities Act.

    
      	
              Dated:___________________

            	
              _________________________________

              (Signature
                must conform to name of holder as

              specified
                on the face of the Warrant)

               

              _________________________________

              _________________________________

              (Address)

            

    

     

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

       

    

    Exhibit B

    

    FORM
      OF
      TRANSFEROR ENDORSEMENT

    (To
      be
      signed only on transfer of Warrant)

     

    For
      value
      received, the undersigned hereby sells, assigns, and transfers unto the
      person(s) named below under the heading “Transferees” the right represented by
      the within Warrant to purchase the percentage and number of shares of Common
      Stock of The Medical Exchange Inc.. to which the within Warrant relates
      specified under the headings “Percentage Transferred” and “Number Transferred,”
respectively, opposite the name(s) of such person(s) and appoints each such
      person Attorney to transfer its respective right on the books of The Medical
      Exchange Inc. with full power of substitution in the premises.

     

    
      	
              Transferees

            	
              Percentage
                Transferred

            	
              Number
                Transferred

            
	 	 	 
	 	 	 
	 	 	 

    

    

    

    
      	
              Dated:
                ______________, ___________

               

               

               

              Signed
                in the presence of:

               

              ____________________________

              (Name)

               

               

              ACCEPTED
                AND AGREED:

              [TRANSFEREE]

               

               

              ____________________________

              (Name)

            	
              __________________________________________

              (Signature
                must conform to name of holder as specified 

              on
                the face of the warrant)

               

               

               

              __________________________________________

              __________________________________________

              (address)

               

              __________________________________________

              __________________________________________

              (address)

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00122-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00122-of-00352.parquet"}]]